Colinz Laboratories Ltd.

BSE: COLINZ · Pharmaceuticals · sector

₹63.04BSE close 2026-10-26

Key numbers

Market cap₹16 cr

Price₹63.04

52w high / low₹88 / ₹36

P/E5.7xSector median 27.9x

P/B1.6xSector median 2.9x

Book value₹39.9

Dividend yield–Sector median 0.48%

ROE28.7%Sector median 11.7%

ROCE33.3%Sector median 12.3%

OPM53.3%Sector median 14.0%

Debt / equity0.04xSector median 0.16x

EV/EBITDA2.5xSector median 18.6x

Interest cover82.3x

Current ratio3.68x

Sales growth 3y-5.0%Sector median +9.6%

Profit growth 3y+3.8%Sector median +13.3%

PEG1.47x

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹9 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 82.3x in the last 12 months.
Other income was 19% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹63.04 on 2026-10-26: -28.3% from the 52-week high, +74.6% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹85.92 · low ₹39.42

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1	2	1	1	2	1
EBITDA	0	0	0	0	0	3
OPM %	6.9%	8.9%	5.8%	7.0%	5.1%	228.2%
Other income	0	0	0	0	0	0
Net profit	0	0	0	0	0	2
EPS (₹)	0.60	0.54	0.56	0.33	0.68	9.53
Revenue YoY					+20.7%	-21.0%
Profit YoY					+13.3%	+1,900.0%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	7	7	7	7	6	6
EBITDA	1	1	1	0	0	3
Net profit	0	0	0	0	1	3
EPS (₹)	0.74	1.82	1.93	1.97	2.04	11.10
Revenue growth		+2.7%	-1.8%	-7.1%	-6.0%	–
Profit growth		+35.3%	+6.5%	+2.0%	+2.0%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	-5.0%	–	–
Net profit	+3.8%	–	–
EPS	+3.9%	–	–
Share price	–	+11.0% (2y)	+59.5%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	9	10
Borrowings	1	0
Cash & equivalents	6	9
Total assets	12	13
Fixed assets	2	2
Capital work in progress	0	0
Investments	1	1
Receivables	1	1
Inventory	1	1
Payables	1	0

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-1	3
Cash from investing	0	0
Cash from financing	-0	-0
Capex	0	0
Free cash flow	-2	3

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	5.2%	5.1%
ROCE %	6.5%	7.1%
Debtor days	37	50
Inventory days	136	150
Payable days	95	82
Cash conversion cycle (days)	78	118
Working capital days	383	437

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
COLINZ	₹16 cr	5.7x	1.6x	28.7%	33.3%	53.3%	-5.0%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	COLINZ
BSE code	531210
ISIN	INE923C01011
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.